Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Fisher Wallace manufactures and markets wearable medical devices for the treatment...
Fisher Wallace manufactures and markets wearabl...
Connector LLC is a corporation that creates highly cost-effective platforms for se...
Connector LLC is a corporation that creates hig...
Aytu is committed to better health for men and women here at home and worldwide. W...
Aytu is committed to better health for men and ...
With a focus on the development of small molecule drugs for the treatment of cance...
With a focus on the development of small molecu...
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on ap...
InflaRx (Nasdaq: IFRX) is a clinical-stage biop...
Progenics develops innovative medicines and other technologies to target and treat...
Progenics develops innovative medicines and oth...
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
Join the National Investor Network and get the latest information with your interests in mind.